 |
|
 |
|
|
|
 What is RSS?
Union discontent over NHS pay deal
Three major healthcare worker unions have expressed their dissatisfaction with the Government pay deal for more than a million NHS staff, and could now block the exhaustively negotiated agreement...(more)
Dry pipelines undermining EMEA
A dramatic drop in new drug applications is now threatening Europe medicines regulator the EMEA with a financial crisis, and could hinder plans to expand its role...(more)
Salt and water undermine $33bn hypertension market
A new study claims that generic salt and water diuretics work as well as two of the biggest selling anti-hypertension treatments in lowering blood pressure, promising huge savings for health systems...(more)
SP website promotes rheumatoid arthritis guidance
Schering-Plough has set up a website to promote NHS uptake of NICE guidance on Remicade, its rheumatoid arthritis product...(more)
McClellan pledges DTC clampdown
Mark McClellan the newly appointed FDA Chief Commissioner has pledged to clamp down on misleading US direct to consumer advertising by pharmaceutical companies...(more)
Merck to file cholesterol combination in 2003
Merck has revealed its plans for double-digit growth for 2003 including a new cholesterol pill combining its blockbuster Zocor with Schering-Plough recently approved Zetia...(more)
PCTs given £148bn for three-year budgets
Primary care trusts in England have been allocated a total of £148.3 billion for the next three years, representing a 30% average increase to meet growing cost pressures...(more)
MCA modernises IT systems
The MCA is to spend £50 million on modernising its IT systems to allow more electronic communication with stakeholders, including the pharmaceutical industry...(more)
MCA under fire as Schering withdraws pill ad
The Medicines Control Agency has come under criticism following the withdrawal of Schering Health Care UK adverts for its contraceptive pill Yasmin...(more)
Foundation hospital plans face Labour revolt
The Government is set to face a major revolt by Labour backbenchers against its plans for foundation hospitals, which have now been finalised...(more)
Limited NICE recommendation for Lantus
The National Institute of Clinical Excellence has issued guidance on Aventisdiabetes treatment Lantus, but has not recommended it as a routine treatment for type 2 diabetes...(more)
GSK in IT outsourcing talks
GlaxoSmithKline is in talks with suppliers to contract out part of its IT services, potentially putting hundreds of UK jobs at risk...(more)
AstraZeneca restructures UK marketing team
AstraZeneca has assembled a team of leading executives to head up a new restructured UK marketing team...(more)
Pfizer/Pharmacia merger gets shareholder go-ahead
Shareholders of Pfizer and Pharmacia have overwhelmingly voted in favour of the proposed $60 billion merger of the two US companies...(more)
End clinical trials 'chaos' with register, says BMJ
The British Medical Journal has called for all clinical trials within Europe to be registered in a central database...(more)
Atypical antipsychotics still underprescribed
Thousands of people with schizophrenia are still being denied access to the newer atypical antipsychotics six months after NICE issued guidance on the drugs...(more)
Ministers to rule on NICE timing
Ministers are to have the final say on when NICE reviews new drugs, and could delay appraisals on the advice of the industry and the Department of Health Technologies Advisory Group...(more)
Bad omens for NHS patient involvement
The exclusion of frontline NHS staff from early work on patientsforums does not bode well for the future of the bodies, a new report warns...(more)
Breckenridge to be MHRA Chairman
Prof Alasdair Breckenridge has been appointed to head up the new Medicines and Healthcare Products Regulatory Agency...(more)
PowderJect won't be 'sold on the cheap'
PowderJect has rejected a £405 million takeover bid from US rival Chiron, with chief executive Paul Drayson saying the company wouldn be old on the cheap..(more)
Guide to medicines review launched
The medicines review process could transform the quality of prescribing if used properly, according to a new guide...(more)
Biotech strategy plan gets EU backing
The European Union has acknowledged the need for a strong biotech industry by the adoption of a strategy it hopes will lead to a more competitive biotech sector...(more)
Long awaited diabetes NSF in sight, but no new money
The NHS will receive no extra money to deliver the long awaited national service framework for diabetes when it is announced in the coming weeks, senior health service figures have indicated...(more)
Garnier pay defeat signals shareholder power shift
GlaxoSmithKline Chief Executive Jean-Pierre Garnier has suffered an embarrassing defeat at the hands of company shareholders in a row over a proposed $18 million (£11 million) pay deal...(more)
ABPI collaborates on diabetes website for Scotland
The ABPI Scottish Diabetes Industry Group (SDIG) and the Scottish Executive have collaborated on a new website to raise public awareness of the growing problem of diabetes in Scotland...(more)
S-P's Zetia gains US approval
Schering-Plough Zetia, the first in a new class of cholesterol-lowering drugs that slow intestinal absorption of cholesterol has gained FDA approval...(more)
Dolly's PR merges into new communications consultants
Sue Charles, the PR executive who broke the news of Dolly the Sheep to the world, is to head up a new merged agency to be called Northbank Communications...(more)
EU suspends Pfizer/Pharmacia merger review
The European Union has put on hold its review of the proposed merger of Pfizer and Pharmacia merger, delaying the $60 billion deal until well into 2003...(more)
|
|
|
|
|
|
|
|
|
|
|
